S-1: Endovia Health Sciences Files S-1 for Stock Resale

Endovia Health Sciences, Inc. has filed an S-1 registration statement to allow for the resale of up to 1,013,041 shares of its common stock by C/M Capital Master Fund, LP.

Summary

• Endovia Health Sciences, Inc. (formerly Splash Beverage Group, Inc.) has filed a Form S-1 registration statement concerning the potential resale of up to 1,013,041 shares of its common stock by C/M Capital Master Fund, LP.
• The company is undergoing a strategic transformation from a beverage business to focusing on the cannabinoid and health and wellness markets, highlighted by the acquisition of exclusive worldwide rights to the pharmaceutical product CannEpil.
• Endovia faces significant financial challenges, including recurring losses, a working capital deficit, and substantial doubt about its ability to continue as a going concern, as noted by its auditors.
• The company is at high risk of being delisted from the NYSE American due to failing to meet continued listing requirements, particularly the stockholders' equity requirement, with a compliance plan in place until January 29, 2027.
• The company has an equity line of credit (ELOC) with C/M Capital Master Fund, LP, through which it may sell shares to raise capital, but the proceeds are intended for working capital, resolving disputes, and general corporate purposes.
• The filing details numerous risks, including the need for additional capital, potential dilution from future stock sales, the uncertainty of developing and commercializing CannEpil, and ongoing legal proceedings.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's precarious financial condition, ongoing going concern issues, and significant risks of delisting from the NYSE American.

Positives

• Strategic pivot towards the growing cannabinoid and health and wellness markets.
• Acquisition of exclusive worldwide rights to CannEpil, a pharmaceutical product for epilepsy and neurological conditions.
• Entry into a development and collaboration agreement for CannEpil's veterinary applications.
• Secured an equity line of credit (ELOC) with C/M Capital Master Fund, LP, providing potential access to capital.
• Recent appointment of experienced management in the cannabinoid sector.

Negatives

• Auditors have issued a going concern warning due to recurring losses, negative cash flows, and a working capital deficit.
• High risk of delisting from the NYSE American due to failure to meet continued listing standards, particularly stockholders' equity.
• The company has not generated revenue from the CannEpil license to date.
• Significant outstanding debt and potential for further dilution to existing shareholders from future stock issuances.
• Ongoing legal proceedings and disputes, including a significant settlement with Decathlon Alpha IV, L.P.
• Limited cash resources and reliance on external financing to fund operations and development.

Risks

• Substantial doubt about the company's ability to continue as a going concern.
• Risk of delisting from the NYSE American due to non-compliance with continued listing standards, particularly the stockholders' equity requirement.
• Inability to raise sufficient additional capital on favorable terms or at all, which could force the company to cease operations.
• The CannEpil license may not yield anticipated benefits, and intellectual property protection is limited.
• Challenges in developing, obtaining regulatory approval for, and commercializing CannEpil for human and veterinary use.
• Potential for significant dilution to existing stockholders from future sales of common stock under the ELOC and conversion of outstanding securities.
• The company's stock price has been volatile and may continue to decline, potentially leading to devaluation or worthlessness.
• Ongoing legal proceedings and potential for adverse outcomes that could materially harm the business.

Future Outlook

The company aims to transition to the regulated wellness and cannabinoid markets, focusing on the development and commercialization of CannEpil. Future success is heavily dependent on securing additional capital, achieving regulatory approvals, and successfully executing strategic transactions, including potential mergers or acquisitions, to regain compliance with NYSE American listing standards.

Management Comments

• Management is seeking to position the Company to capitalize on the ongoing evolution of the cannabinoid and wellness economy by attempting to identify, partner with, and support established brands across the hemp-derived CBD and, subject to applicable regulatory and exchange approvals, medical cannabis marketplaces.
• Management believes the company's public platform, industry relationships and leadership experience present opportunities to participate in higher-growth segments of the cannabinoid health and wellness industry.
• Management believes the experience of its interim leadership provides the Company with a differentiated perspective as it evaluates opportunities across pharmaceutical, wellness and consumer cannabinoid markets.

Industry Context

StockSavvy.ai notes that Endovia's pivot to the cannabinoid and wellness sector aligns with a broader industry trend of companies seeking growth in these rapidly evolving markets. However, the company faces intense competition and a complex regulatory landscape, particularly concerning FDA approvals for therapeutic products.

Comparison to Industry Standards

• The company's financial situation, characterized by significant losses and a going concern warning, is a stark contrast to established, profitable players in the pharmaceutical and wellness sectors.
• The risk of delisting from the NYSE American is a critical concern, as major exchanges typically require companies to demonstrate a certain level of financial stability and market capitalization, which Endovia currently lacks.
• The development timeline and regulatory hurdles for bringing a cannabinoid-based therapeutic like CannEpil to market are substantial, requiring significant investment and expertise, areas where Endovia acknowledges a lack of experience.
• Competitors in the cannabinoid space, such as Trulieve (which recently listed on the NYSE), have demonstrated a path to market and regulatory compliance, setting a benchmark for success in the industry.

Legal Proceedings

• TapouT, LLC is seeking approximately $1,700,000 for breach of contract and accounts stated related to a terminated licensing agreement.
• The company is resolving alleged and potential claims from investors referred to as the Uptime Investor Claims.
• A demand for payment was received from Decathlon Alpha IV, L.P. for approximately $2.8 million related to a Revenue and Loan Security Agreement.
• Premium Merchant Funding 26, LLC filed a complaint for breach of contract seeking approximately $166,516, with a default judgment entered.
• A demand for payment of $2,000,000 was made by counsel for Jeremy Reichman, Albert Reichman, Seth Yanofsky, and Daniel Braun for alleged failure to pay compensation under consulting agreements.
• Copa Di Vino Corporation filed a complaint alleging breach of a settlement agreement, seeking accelerated payment of approximately $788,000 plus interest and costs.

Related Party Transactions

• Sublease of office space from Northswell Consulting, LLC, an entity owned by Brady Cobb, for $4,750 per month.
• Consulting agreement with William Meissner (former President) for $5,000 per month, plus stock options.
• Consulting agreement with Robert Nistico (former CEO and Director) for $5,000 per month, plus stock options, and reimbursement of $31,000 in expenses.
• Outstanding related party payables to former CEO Robert Nistico, with interest rate discussions ongoing.
• Issuance of 1,000 shares of Series A Preferred Stock to Robert Nistico, which were subsequently redeemed.

Stakeholder Impact

• Shareholders face significant dilution risk from future stock sales and potential devaluation of their investment if the company fails to secure capital or avoid delisting.
• Creditors may face delays or non-payment of outstanding amounts, with an estimated $4.7 million owed to certain creditors.
• Employees may face uncertainty regarding job security given the company's financial precariousness and ongoing strategic transformation.

Next Steps

• Complete the development and commercialization of CannEpil.
• Obtain necessary regulatory approvals for CannEpil in the U.S. and other jurisdictions.
• Identify, negotiate, and complete a strategic transaction (merger or acquisition) to regain compliance with NYSE American listing standards.
• Secure additional capital to fund operations, development, and strategic initiatives.
• Continue to pursue settlement discussions for outstanding legal matters.

Key Dates

Recommendation

The company's severe financial distress, including a going concern warning, high risk of delisting, and substantial ongoing litigation, presents an extremely high-risk investment profile. The strategic pivot and potential capital raises are overshadowed by the immediate threats to its continued operation and listing status.

Keywords

Endovia Health Sciences, Cannabinoid, Health and Wellness, CannEpil, SEC Filing, Form S-1, Equity Line of Credit, NYSE American